Maastricht University
Maastricht, 6200 MD, Netherlands
NCT Number: NCT00402623
The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.
Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Maastricht, 6200 MD, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1000 mg quercetin within 24 hours
Time frame: 24 hours
Time frame: 24 hours
Time frame: 24 hours
Time frame: 24 hours
Maastricht University Medical Center
Other
The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00512967
COPD, Chronic Disease
Maastricht, Netherlands
View Trial DetailsNCT07384897
Bronchial Neoplasms, Carcinoma, Bronchogenic
Brussels, Belgium
View Trial DetailsNCT03814317
Cardiovascular Diseases, Hemic and Lymphatic Diseases
Gainesville, Florida, United States
View Trial DetailsNCT01610843
Hemic and Lymphatic Diseases, Hypersensitivity
Iowa City, Iowa, United States
View Trial Details